Immix Biopharma is trading at $8.98, with a -5.37% change, alongside biotech-sector weakness; no confirmed company-specific catalyst for the October 8 decline was identified.
- Supplied context reports XBI down 2.04%, amid broader risk-off pressure.
- Recent clinical updates and the September share offering are earlier developments, not a clear catalyst for this session.
- Intraday volume details were not available.